eFFECTOR Therapeutics, Inc. EFTR
0.00 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.0002 Day range 0.0002
0.0002 52-week range 0.0008
- YTD
- +300.00%
- 1 year
- +33.33%
News
defenseworld.net Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS) Volatility and Risk eFFECTOR Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 3.44, suggesting that its…
defenseworld.net eFFECTOR Therapeutics (NASDAQ:EFTR) & NexImmune (NASDAQ:NEXI) Critical Contrast Profitability This table compares eFFECTOR Therapeutics and NexImmune's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets eFFECTOR Therapeutics N/A N/A…
newsfilecorp.com BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that…
investorplace.com 3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off As the stock market hits new highs in July, investors are riding a wave of optimism, closely tracking climbing indexes. Yet, beneath this bullish surface, some publicly traded companies are becoming…
globenewswire.com eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind…
globenewswire.com eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors…
investorplace.com EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024 eFFECTOR Therapeutics (NASDAQ: EFTR ) just reported results for the first quarter of 2024. eFFECTOR Therapeutics reported earnings per share of -$2.16.
globenewswire.com eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway…
globenewswire.com eFFECTOR Therapeutics to Participate in Upcoming Investor Conference SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors…
zacks.com eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails eFFECTOR Therapeutics (EFTR) plunges on disappointing top-line results from the primary analysis of its mid-stage NSCLC study of tomivosertib, following the abandonment of the developmental program.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
globenewswire.com eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors…
globenewswire.com eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
globenewswire.com eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors…
zacks.com Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect? The average of price targets set by Wall Street analysts indicates a potential upside of 814.5% in eFFECTOR Therapeutics, Inc. (EFTR). While the effectiveness of this highly sought-after metric is…
globenewswire.com eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation…
globenewswire.com eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation…
globenewswire.com eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 - Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansion…
globenewswire.com eFFECTOR Therapeutics Announces Reverse Stock Split EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
benzinga.com Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket Shares of LumiraDx Limited (NASDAQ: LMDX) shares fell sharply in pre-market trading. LumiraDx announced its securities will be suspended from trading on Nasdaq at the open of business on Jan. 9th.…- benzinga.com Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at…
benzinga.com Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are…
globenewswire.com eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients
globenewswire.com eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor
benzinga.com Why StoneCo Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket StoneCo Ltd. (NASDAQ: STNE) shares rose in pre-market trading after the company reported upbeat results for its third quarter on Friday.- benzinga.com Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
- benzinga.com Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.
benzinga.com Why Hitek Global Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket Gainers
benzinga.com S&P 500 Down 2%; Mobilicom Shares Spike Higher U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The…
benzinga.com Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 72 companies hit new 52-week lows.
benzinga.com Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.- benzinga.com Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products…
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 298 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 79 companies reached new 52-week lows.- benzinga.com Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in…
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 122 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 529 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 100 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 550 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's session, 326 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 153 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 1043 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 213 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 166 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 95 companies set new 52-week lows.